Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection

Clin J Am Soc Nephrol. 2008 Sep;3(5):1479-86. doi: 10.2215/CJN.04451007. Epub 2008 Jun 25.

Abstract

Background and objectives: Anti-endothelial cell antibody (AECA) can cause hyperacute rejection and immediate graft loss after renal transplantation; however, its prevalence and significance during acute rejection are unknown. Previous studies suggested that AECA may be detected in recipients with acute vascular rejection (AVR).

Design, setting, participants, & measurements: We retrospectively analyzed 653 cadaveric renal transplant recipients; circulating AECA was positive in 13 of 47 cases of AVR; another two cases of hyperacute rejection also had detectable AECA. Twenty-six cases of AVR without circulating AECA were selected as controls.

Results: AECA-positive AVR usually occurred within 1 yr after transplantation and mostly was resistant to steroid treatment. Compared with the control group, the AECA-positive group was associated with a significantly lower 1-yr graft survival rate (46.7 versus 80.5%; P = 0.038), and more patients had histologic interstitial plasma cell infiltration (53.8 versus 11.5%; P = 0.005). More patients with AECA-positive AVR experienced another one or more episodes of acute rejection during 1 yr of follow-up (75.0 versus 13.0%; P = 0.003). AECA-positive AVR with C4d deposition in peri-tubular capillaries had the worst outcome in this cohort, and it accounted for 38.5% graft loss in AVR. AECA in turn accounted for 71.4% of graft loss in C4d(+) AVR.

Conclusions: Circulating AECA is associated with poor outcome in renal allograft recipients with acute rejection and should be monitored regularly.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Autoantibodies / blood*
  • Cadaver
  • Capillaries / immunology
  • Complement C4b / analysis
  • Endothelial Cells / immunology*
  • Endothelial Cells / pathology
  • Female
  • Graft Rejection / immunology*
  • Graft Rejection / mortality
  • Graft Rejection / pathology
  • Graft Rejection / therapy
  • Graft Survival / immunology*
  • HLA Antigens / immunology
  • Humans
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Peptide Fragments / analysis
  • Retrospective Studies
  • Time Factors
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Autoantibodies
  • HLA Antigens
  • Peptide Fragments
  • anti-endothelial cell antibody
  • Complement C4b
  • complement C4d